MISSISSAUGA, Ontario, Nov. 13 /PRNewswire-FirstCall/ -- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the immunoassay segment of the IVD testing market, was featured in Medical Device Daily's November 12, 2009 edition.
The article by Amanda Petersen, titled "CardioGenics aims to offer faster heart attack diagnosis," shares insights from CardioGenics CEO Yahia Gawad, MD regarding the company's point-of-care (POC) cardiac diagnostic technology. This technology includes the QL Care® Analyzer, designed to provide a more rapid diagnosis of heart attacks, to meet the guidelines established by the American Heart Association and the American College of Cardiology. It also includes the company's highly reflective paramagnetic beads, intended as a more light-sensitive alternative to beads currently used in 90% of medical lab analyzers.
The Medical Device Daily piece explains, "Speed of diagnosis is important when physicians are dealing with possible heart attack patients because they need to decide quickly how they are going to treat the patient, if they are going to be aggressive or use a more conservative therapy." In the article, Dr. Gawad notes, "For every hour you delay treating the patient it costs three lives, so the time is extremely important." Equally crucial, the article reports Gawad as saying, is the need to base that treatment decision on a sound diagnosis. The use of this POC test could reduce healthcare costs and offer faster diagnosis, Gawad states in the article.
The article goes on to describe the single-use cartridge QL Care® Analyzer, which CardioGenics states as offering a "quantum leap" in existing POC immunoassay technology: "In just six steps, the QL Care® Analyzer provides printed medical lab quality results in less than fifteen minutes." Gawad is reported in the article as noting that the company's initial target for the device is emergency rooms, chest pain clinics, and cardiac care units, but could be used in ambulances as well. CardioGenics is also reported as anticipating that the device cartridge can be ultimately adapted to run any number of immunoassay tests.
The article goes on to describe CardioGenics' other lead product, silver-coated magnetic beads that are more reflective and capable of delivering sensitivity five-to-ten times higher than competitive products in the chemiluminescence testing space.
The Medical Device Daily article is available online at http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=68998.
About CardioGenics Holdings Inc.
CardioGenics is dedicated to developing more sensitive diagnostic test products for the IVD market. CardioGenics has started several developmental processes aimed to achieve its objective "to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies." CardioGenics' operating philosophy is that "better diagnosis enhances the healthcare professionals' ability to provide better patient management which saves lives and reduces healthcare costs." Fulfilling unmet clinical testing needs is the driving force behind CardioGenics' innovations. Its current products include the QL Care Analyzer ("QLCA"), a state-of-the-art proprietary point of care ("POC") immunoanalyzer; a series of immunoassay tests to detect cardiac markers; and a proprietary method for improving the light collection from paramagnetic beads ("Beads"). You can learn more about CardioGenics at (cardiogenics.com).
SOURCE CardioGenics Holdings Inc.
|SOURCE CardioGenics Holdings Inc.|
Copyright©2009 PR Newswire.
All rights reserved